Choroidal neovascularisation in pathological myopia: An update in management

British Journal of Ophthalmology

Volumn 89, Issue 11, 2005, Pages 1522-1528

  Chan, Wai Man ^a,b   Ohji, M ^c   Lai, T Y Y ^a   Liu, D T L ^b   Tano, Y ^c   Lam, D S C ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; CORTICOSTEROID; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN;

ASIAN; CLINICAL FEATURE; CLINICAL TRIAL; EYE SURGERY; FLUORESCENCE ANGIOGRAPHY; HUMAN; INCIDENCE; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; MACULA TRANSLOCATION SURGERY; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RETINOTOMY; REVIEW; SUBMACULAR SURGERY; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

CHOROIDAL NEOVASCULARIZATION; HUMANS; LASER COAGULATION; MACULA LUTEA; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY;

EID: 27344435450     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.074716     Document Type: Review

References (91)

1. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983;67:209-13.
2. Curtin BJ, Karlin DB. Axial length measurement and fundus changes of the myopic eyes. Am J Ophthalmol 1971;71:42-50.
3. Noble KG, Carr RE. Pathologic myopia. Ophthalmology 1982;89:1099-100.
4. Lin LL, Shih YF, Hsiao CK, et al. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singapore, 2004;33:27-33.
5. Wong TY, Foster PJ, Hee J, et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthalmol Vis Sci 2000;41:2486-94.
6. Hofman A, Grobbee DE, de Jong PT, et al. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-22.
7. Wang Q, Klein BE, Klein R, et al. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1994;35:4344-7.
8. Raju P, Ve Ramesh S, Arvind H, et al. Prevalence of refractive errors in a rural south Indian population. Invest Ophthalmol Vis Sci 2004;45:4268-72.
9. Attebo K, Ivers RQ, Mitchell P. Refractive errors in an older population: the Blue Mountains Eye Study. Ophthalmology 1999;106:1066-72.
10. Curtin BJ, Iwamoto T, Renaldo DP. Normal and staphylomatous sciera in high myopia: an electron microscopic study. Arch Ophthalmol 1979;97:912-5.
11. McBrien NA, Norton TT. Prevention of collagen crosslinking increases form deprivation myopia in tree shrew. Exp Eye Res 1994;59:475-86.
12. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992;12:127-33.
13. Hotchkiss ML, Fine SL. Pathological myopia and choroidal neovascularization. Am J Ophthalmol 1981;91:177-83.
14. Fried M, Siebert A, Meyer-Schwickerath G. A natural history of Fuchs' spot: a long term follow-up study. Doc Ophthalmol 1981;28:215-21.
15. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-81.
16. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90:923-6.
17. Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103:1241-4.
18. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003;87:570-3.
19. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-Year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108:841-52.
20. Yannuzzi LA, Slakter JS, Sorenson JA, et al. Digital indocyanine green video angiography and choroidal neovascularization. Retina 1992;12:191-223.
21. Quaranta M, Arnold J, Coscas G, et al. Indocyanine green angiographic features of pathologic myopia. Am J Ophthalmol 1996;122:663-71.
22. Brancato R, Trabucchi G, Introini U, et al. Indocyanine green angiography (ICGA) in pathological myopia. Eur J Ophthalmol 1996;6:39-43.
23. Ohno-Matsui K, Morishima N, Ito M, et al. Indocyanine green angiographic findings of lacquer cracks in pathologic myopia. Jpn J Ophthalmol 1998;42:293-9.
24. Axer-Siegel R, Cotlear D, Priel E, et al. Indocyanine green angiography in high myopia. Ophthalmic Surg Lasers Imaging 2004;35:139-45.
25. Costa RA, Calucci D, Teixeira LF, et al. Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 2003;135:857-60.
26. Baba T, Ohno-Matsui K, Yoshida T, et al. Optical coherence tomography of choroidal neovascularization in high myopia. Acta Ophthalmol Scand 2002;80:82-7.
27. Zolf R, Glacet-Bernard A, Benhamou N, et al. Imaging analysis with optical coherence tomography: relevance for submacular surgery in high myopia and in multifocal choroiditis. Retina 2002;22:192-201.
28. Marmor MF, Hood DC, Keating D, et al. Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol 2003;106:105-15.
29. Jurklies B, Weismann M, Husing J, et al. Monitoring retinal function in neovascular maculopathy using multifocal electroretinography: early and long-term correlation with clinical findings. Graefes Arch Clin Exp Ophthalmol 2002;240:244-64.
30. Moschos MN, Panayotidis D, Moschos MM, et al. A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy. Eur J Ophthalmol 2003;13:461-7.
31. Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram following photodynamic therapy. Am J Ophthalmol 2004;137:826-33.
32. Koboyashi K, Mandai M, Suzuma I, et al. Expression of estrogen receptor in the choroidal neovascular membranes in highly myopic eyes. Retina 2002;22:418-22.
33. Secretan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7:307-16.
34. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-7.
35. Bottoni F, Tilanus M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int Ophthalmol 2001;24:249-55.
36. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. Ophthalmology 2002;109:712-19.
37. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;100:1297-305.
38. Hayashi K, Ohno-Matsui, Yoshida T. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005;243:13-19.
39. Kojima A, Ohno-Matsui K, Teramukai S, et al. Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2004;242:114-19.
40. Jalkh AE, Weiter JJ, Trempe CL, et al. Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg 1987;18:721-5.
41. Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. Am J Ophthalmol 1997;123:181-7.
42. Pece A, Brancato R, Avanza P, et al. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol 1994;18:339-44.
43. Oshima Y, Harino S, Tano Y. Scanning laser ophthalmoscope microperimetric assessment in patients with successful laser treatment for juxtafoveal choroidal neovascularization. Retina 1998;18:109-17.
44. Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 2002;12:117-22.
45. Morgan CM, Schatz H. Atrophic creep of the retinal pigment epithelium after focal macular photocoagulation. Ophthalmology 1989;96:96-103.
46. Brancato R, Pece A, Avanza P, et al. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990;10:239-43.
47. Johnson DA, Yannuzzi LA, Shakin JL, et al. Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 1998;18:118-24.
48. Maziere JC, Morliere P, Santus R. The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours. J Photochem Photobiol B 1991;8:351-60.
49. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214.
50. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehardt U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-44.
51. Husain D, Miller JW, Michaud N, et al. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996;114:978-85.
52. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-73.
53. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of two randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117:1329-45.
54. Bressler NM, Arnold J, Benchaboune M, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report no 3. Arch Ophthalmol 2002;120:1443-54.
55. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no 3. Ophthalmology 2003;110:667-73.
56. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003;87:173-6.
57. Ruiz-Moreno JM, Montero JA. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 2003;87:856-9.
58. Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularisation in pathologic myopia. Am J Ophthalmol 2004;138:434-8.
59. Lam DS, Chan WM, Liu DT, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization of pathologic myopia in Chinese eyes - a prospective series of 1 and 2 year follow up. Br J Ophthalmol 2004;88:1315-19.
60. Bandello F, Lanzetta P, Battaglia Parodi M, et al. Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2003;241:567-70.
61. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation, II: surgical approach forage-related macular generation? Graefes Arch Clin Exp Ophthalmol 1993;231:635-41.
62. Fujikado T, Ohji M, Saito Y, et al. Visual function after foveal translocation with scleral shortening in patients with myopic neovascular maculopathy. Am J Ophthalmol 1998;125:647-56.
63. Chan WM, Lam DS, Liu DT, et al. Photodynamic therapy for recurrent myopic choroidal neovascularization after limited macular translocation surgery. Br J Ophthalmol 2003;87:1188-9.
64. Cohen SY, Bulik A, Dubois L, et al. Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am J Ophthalmol 2003;136:371-4.
65. Lam DS, Liu DT, Fan DS, et al. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia: one-year results of a prospective series. Eye 2005;19:834-40.
66. Ladas LD, Moschos MM, Rouvas AA, et al. Lacquer crack formation after photodynamic therapy. Eur J Ophthalmol 2003;13:729-33.
67. Gelisken F, Inhoffen W, Hermann A, et al. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2004;242:926-30.
68. Thomas MA, Dickinson JD, Melberg NS, et al. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994;101:1384-96.
69. Adelberg DA, Del Priore LV, Kaplan HJ. Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina 1995;15:198-205.
70. Benson MT, Callear A, Tsaloumas M, et al. Surgical excision of subfoveal neovascular membranes. Eye 1998;12:768-74.
71. Bottoni F, Perego E, Airaghi P, et al. Surgical removal of subfoveal choroidal neovascular membranes in high myopia. Graefes Arch Clin Exp Ophthalmol 1999;237:573-82.
72. Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 2000;118:344-50.
73. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001;85:1041-3.
74. Hamelin N, Glacet-Bernard A, Brindeau C, et al. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol 2002;133:530-6.
75. Glacet-Bernard A, Simon P, Hamelin N, et al. Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia. Am J Ophthalmol 2001;131:78-89.
76. Ichibe M, Imai K, Ohta M, et al. Foveal translocation with scleral imbrication in patients with myopic neovascular maculopathy. Am J Ophthalmol 2001;132:164-71.
77. Fujii GY, Humayun MS, Pieramici DJ, et al. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol 2001;131:90-100.
78. Tano Y. Pathologic myopia: where are we now? Am J Ophthalmol 2002;134:645-60.
79. Mateo C, Moreno J, Rosales G, et al. Two-year results of macular translation with scleral infolding in myopic choroidal neovascularisation. Sem Ophthalmol 2004;19:29-42.
80. Fujii GY, Pieramici DJ, Humayun MS, et al. Complications associated with limited macular translocation. Am J Ophthalmol 2000;130:751-62.
81. Fujikado T, Ohji M, Hosohata J, et al. Comparison of visual function after foveal translocation with 360 degrees retinotomy and with scleral shortening in a patient with bilateral myopic neovascular maculopathy. Am J Ophthalmol 2000;130:525-7.
82. Fujikado T, Ohji M, Kusaka S, et al. Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy. Am J Ophthalmol 2001;131:101-10.
83. Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:313-25.
84. Kobayashi H, Kobayashi K. Radiotherapy for subfoveal neovascularisation associated with pathological myopia: a pilot study. Br J Ophthalmol 2000;84:761-6.
85. Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-11.
86. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.
87. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372-83.
88. Alcon, Inc. Alcon announces anecortave acetate clinical results (invest.alconinc.com/phoenix.zhtml? c = 130946&p = irol-news Article&ID = 630541&highlight), accessed 4 June, 2005.
89. Krzystolilc MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46.
90. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
91. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-16.